These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29672039)

  • 1. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.
    Bagal SK; Omoto K; Blakemore DC; Bungay PJ; Bilsland JG; Clarke PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; Johnson E; Fengas D; Kitching L; Kraus ML; McAlpine I; Nagata A; Waldron GJ; Warmus JS
    J Med Chem; 2019 Jan; 62(1):247-265. PubMed ID: 29672039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.
    Bagal SK; Andrews M; Bechle BM; Bian J; Bilsland J; Blakemore DC; Braganza JF; Bungay PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; James K; Johnson E; Kitching L; Kraus ML; McAlpine I; Nagata A; Ninkovic S; Omoto K; Scales S; Skerratt SE; Sun J; Tran-Dubé M; Waldron GJ; Wang F; Warmus JS
    J Med Chem; 2018 Aug; 61(15):6779-6800. PubMed ID: 29944371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with TrkA kinase.
    Wu X; Li Q; Wan S; Zhang J
    J Biomol Struct Dyn; 2021 Jan; 39(1):202-208. PubMed ID: 31870220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel TrkA allosteric inhibitors: Structure-based virtual screening, biological evaluation and preliminary SAR studies.
    Guo J; Xiang S; Wang J; Zhou Y; Wang Z; Zhang Z; Ding K; Lu X
    Eur J Med Chem; 2022 Jan; 228():114022. PubMed ID: 34871843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
    Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The juxtamembrane region of TrkA kinase is critical for inhibitor selectivity.
    Furuya N; Momose T; Katsuno K; Fushimi N; Muranaka H; Handa C; Ozawa T; Kinoshita T
    Bioorg Med Chem Lett; 2017 Mar; 27(5):1233-1236. PubMed ID: 28159414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.
    Skerratt SE; Andrews M; Bagal SK; Bilsland J; Brown D; Bungay PJ; Cole S; Gibson KR; Jones R; Morao I; Nedderman A; Omoto K; Robinson C; Ryckmans T; Skinner K; Stupple P; Waldron G
    J Med Chem; 2016 Nov; 59(22):10084-10099. PubMed ID: 27766865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition.
    Bertrand T; Kothe M; Liu J; Dupuy A; Rak A; Berne PF; Davis S; Gladysheva T; Valtre C; Crenne JY; Mathieu M
    J Mol Biol; 2012 Oct; 423(3):439-53. PubMed ID: 22902478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a pharmacodynamic biomarker to measure target engagement from inhibition of the NGF-TrkA pathway.
    Price EA; Krasowska-Zoladek A; Nanda KK; Stachel SJ; Henze DA
    J Neurosci Methods; 2017 Apr; 282():34-42. PubMed ID: 28279735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain.
    Stachel SJ; Sanders JM; Henze DA; Rudd MT; Su HP; Li Y; Nanda KK; Egbertson MS; Manley PJ; Jones KL; Brnardic EJ; Green A; Grobler JA; Hanney B; Leitl M; Lai MT; Munshi V; Murphy D; Rickert K; Riley D; Krasowska-Zoladek A; Daley C; Zuck P; Kane SA; Bilodeau MT
    J Med Chem; 2014 Jul; 57(13):5800-16. PubMed ID: 24914455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of deprivation of neonatal nerve growth factor on the expression of neurotrophin receptors and brain-derived neurotrophic factor by dental pulp afferents of the adult rat.
    Pan M; Naftel JP; Wheeler EF
    Arch Oral Biol; 2000 May; 45(5):387-99. PubMed ID: 10739860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An isoform-selective inhibitor of tropomyosin receptor kinase A behaves as molecular glue.
    Furuya N; Momose T; Katsuno K; Fushimi N; Muranaka H; Handa C; Sawa M; Ozawa T; Kinoshita T
    Bioorg Med Chem Lett; 2020 Jan; 30(1):126775. PubMed ID: 31699609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and SAR of substituted indoles as selective TrkA inhibitors.
    Hurzy DM; Henze DA; Cabalu TD; Narayan K; Heller A; Cooke AJ
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2695-2701. PubMed ID: 28465100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
    J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.